A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.
Many lung cancer patients experience difficulties with sexual expression and intimacy, a topic that has long been ignored by doctors and researchers.
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
In women with breast cancer, loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of a protein called PI3K-alpha.
Among melanoma patients treated with PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates.
Taking low doses of aspirin, which inhibits platelet function, after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen.
Yttrium-90 radioembolization is a minimally invasive treatment that may slow disease progression in breast cancer that has metastasized to the liver.
Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.
A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.
A gene not previously associated with breast cancer appears to play a pivotal role in the growth and progression of triple-negative breast cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|